08.30 · Coffee and registration
09.00 · Chairman's opening remarks
Dr. Michael Christensen
Head of Drug Metabolism
Novo Nordisk
09.15 · Getting Value from Your ADME Data: Effective Decision-making in Early Discovery
Dr. Alan P. Beresford
Associate Director: Lead Optimisation
Inpharmatica Ltd.
10.00 · Optimal Early ADME Screening
Dr. Michael Christensen
Head of Drug Metabolism
Novo Nordisk
10.45 · Networking coffee break
11.15 · Histologically Defined Biomarkers in Drug Development
Mr. Martin Shaw
Senior Scientific Officer
Biotrin International Ltd.
12.00 · Increasing Throughput in Pharmacokinetic Studies
Dr. Kelvin Hughes
Technology Manager, Assay Development
GE Healthcare Biosciences
12.45 · Networking Lunch
14.15 · Integration of High Throughput ADME Screening and Pharmacokinetic Simulation for Acceleration of Drug Discovery
Dr. Darwin Cheney
Chief Scientific Officer
Cyprotex
15.00 · In Silico ADME/Tox Prediction: Crossing the Credibility Chasm.
Dr. Gregory Banik
General Manager, Informatics
Bio-Rad Laboratories Inc.
15.45 · Coffee break
16.00 · Systems Biology Approach to In-Silico Modeling of Biological Pathways: Towards Elucidating Molecular Mechanisms of Toxicity
Dr. Gordana Apic
CEO
Cambridge Cell Networks
16.45 · Predictive Toxicogenomics at the Crossroads
Dr. Andreas Hohn
Genedata AG
17.30 · Panel Discussion
This session will provide an opportunity for all day one speakers and delegates to explore key issues that have arisen over the day.
18.00 · Chair's Closing Remarks
18.30 · End of Day One
08.30 · Coffee and registration
09.00 · Chairman's opening remarks
Dr. Terry Riss
R&D Scientist, Cellular Analysis
Promega Corporation
09.15 · Comparison of different materials and surface functionalization technologies for optical bottom plates
Dr. Benedikt Busse, zell-kontakt GmbH,
Mr. Denis J. Moller, Nunc A/S
10.00 · Choosing Appropriate In Vitro Toxicity Assays for Multiplexing
Dr. Terry Riss
R&D Scientist, Cellular Analysis
Promega Corporation
10.45 · Networking coffee break
11.15 · In Vitro Hepatotoxicity Assays in Drug Development
Dr. Nicky Hewitt
European Business Development
In Vitro Technologies Inc
12.00 · Cell-based Models to Study Hepatic Drug Metabolism and Enzyme Induction in Humans
Dr. Willem Meuldermans
Global Sr. Preclin. PK Expert
Johnson & Johnson
12.45 · Networking lunch
14.15 · High Concordance of Drug-Induced Human Hepatotoxicity with in vitro Cytotoxicity Measured in a Novel Cell-based Model Using High Content Screening
Dr. Peter O'Brien
Laboratory Head in Safety Sciences
Pfizer
15.00 · Propagation of Biological and Genetic Interindividual Variability of Metabolism to PK/PD/Tox: Implications for Study Design
Dr. Amin Rostami
Reader in Clinical Pharmacokinetics and Drug Metabolism
University of Sheffield
Director of Scientific Development
Simcyp Limited
15.45 · Coffee break
16.00 · Global In Vitro Predictive Stem Cell Hemotoxicology For Early Drug Screening, Safety Assesment and Estimating Pre-Clinical and Human Clinical Trial Dosing
Dr. Ivan N. Rich
Chairman & CEO
HemoGenix, Inc.
16.45 · Why Pharmacovigilance?
Dr. I. Ralph Edwards
Director, International Drug Monitoring
World Health Organization
17.30 · Panel Discussion
This session will provide an opportunity for all day two speakers and delegates to explore key issues that have arisen over the day.
18.00 · Closing Comments from the Chair
18.30 · Close Conference